Nonrecombinant urate oxidase (Uricozyme, Sanofi-Synth  labo, Inc, Paris, France) is a highly effective uricolytic agent, but its use is associated with @entity56 reaction manifested mainly by @entity5143 in approximately 5% of @entity1 . Recently, several multi-institutional studies have evaluated the efficacy and safety of a recombinant urate oxidase (rasburicase). In a phase I/II study, all 131 @entity1 with newly diagnosed @entity981 ( @entity981 ) or stage III/IV @entity1893 ( @entity1893 ) experienced rapidly decreased plasma @entity414 concentrations after receiving recombinant urate oxidase. Serum @entity1011 levels also decreased significantly. @entity137 was negligible, and none of the @entity1 required dialysis. In a phase III trial, @entity1 with newly diagnosed @entity981 or stage III/IV @entity1893 were stratified and randomized to receive recombinant urate oxidase or @entity208 . Results showed that the 27 @entity1 who received recombinant urate oxidase had a significantly lower plasma @entity414 concentration and a more rapid decline in serum @entity1011 level than did the 25 who took @entity208 . One @entity1 in the recombinant urate oxidase group had @entity2142 of unknown cause, and one in the @entity208 group required hemofiltration for @entity2265 . To further assess the safety profile of recombinant urate oxidase, the data on 245 @entity1 (173 @entity1 and 72 adults) who received this agent in a compassionate-use program were reviewed retrospectively. The drug produced dramatic decreases in @entity414 concentrations in all @entity1 . Nine @entity1 (four @entity1 and five adults) had mild adverse reactions that were drug-related or of unknown etiology. These data suggest that recombinant @entity414 oxidase is safe and effective in the prophylaxis and treatment of @entity5052 associated with @entity5 or chemotherapy.

Urate oxidase in the prophylaxis or treatment of XXXX : the United States experience.

@entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient'] @entity981 :: ('MESH:D054198', 'Disease') :: ['ALL', 'acute lymphoblastic leukemia'] @entity137 :: ('MESH:D064420', 'Disease') :: ['Toxicity'] @entity5052 :: ('MESH:D033461', 'Disease') :: ['hyperuricemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy'] @entity2265 :: ('MESH:D054559', 'Disease') :: ['hyperphosphatemia'] @entity56 :: ('MESH:D004342', 'Disease') :: ['hypersensitivity'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity5143 :: ('MESH:D001986', 'Disease') :: ['bronchospasm'] @entity208 :: ('MESH:D000493', 'Chemical') :: ['allopurinol'] @entity2142 :: ('MESH:D006461', 'Disease') :: ['hemolysis'] @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid', 'urate']
@entity5052 :: (MESH:D033461,Disease) :: ['hyperuricemia']
